Search

Neurological drugs dominate the headlines, and therapeutics from snakes

 

Jack Guglel , co-founder and CEO of Arkana Therapeutics and CU Boulder PhD alum of molecular, cellular and developmental biology, is developing appetite-suppressing molecules discovered through python biology that could offer an alternative to GLP-1 drugs with fewer gastrointestinal side effects.

 

 

 

What could you do with a CU technology?

Venture Partners manages a portfolio of over 1,000 technologies from university investigators and partners with entrepreneurs and companies of all sizes—from startups to the Fortune 500—to bring these inventions to market.

Explore Partnership Opportunities

Turn your discovery into real-world impact

Venture Partners helps researchers, inventors and creators take their groundbreaking discoveries every step of the way, from intellectual property (IP) management to market launch. 

More for University Innovators

 

The Newsroom

Subscribe to Newsletters

The Insider is Venture Partners at CU Boulder's monthly newsletter featuring the latest headlines, news, events, opportunities and emerging innovations from the university. We have several editions for our audiences:

 Subscribe to The Insider  

Media Inquiries

For marketing and communication inquiries or news tips, contact Daniel Leonard, senior marketing and communications specialist for Venture Partners at CU Boulder.

For media inquiries, please visit colorado.edu/news/formedia.

Latest News

Visit the Newsroom